The recommended dose of AROMASIN in early breast cancer is one 25 mg
tablet once daily after a meal.
In postmenopausal women with early breast cancer who have been
treated with 2 to 3 years of tamoxifen, treatment with AROMASIN
should continue in the absence of recurrence or contralateral breast
cancer until completion of 5 years of adjuvant endocrine
therapy.
For patients receiving AROMASIN with a potent CYP 3A4 inducer such
as rifampicin or phenytoin, the recommended dose of AROMASIN is 50 mg
once daily after a meal.
The safety of chronic dosing in patients with moderate or severe
hepatic or renal impairment has not been studied. Based on experience
with exemestane at repeated doses up to 200 mg daily that
demonstrated a moderate increase in non-life threatening adverse
events, dosage adjustment does not appear to be necessary.